Skip Navigation
Print This Page
Share this page: More

Search Results

Genome Wide Admixture for Multiple Myeloma in Africian Americans. (Africian-American MM GWAS)
Protocol Number:
Carol Huff
Multiple myeloma is a malignancy consisting of a neoplastic clone of plasma cells, the terminally-differentiated B lymphocytes responsible for antibody production. In spite of recent therapeutic advances such as Bortezomib or Thalidomide resulting in some improved survival, especially for younger patients1, the overall five-year survival rate remains under 40% for men and women over all ages. MM has a poor survival rate and remains the second leading cause of death due to a hematologic malignancy. Causes are unknown but African Americans experience over two times the risk of Whites and there is strong evidence to suggest a genetic contribution to risk. The goal of this project is to identify genetic determinants of MM, which will lead to a better informed and more targeted approach to disease prevention and treatment.
English speaking Self reported African American Age greater than 20 Physician diagnosed multiple myeloma (including smoldering) diagnosed after July 1, 2008.
Collect blood samples from African American men and women with clinically confirmed MM, and newly diagnosed MM patients after July 1 2008. This is an observational study (no intervention).
Last Update
09/23/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer